Boston, Massachusetts 02215


Purpose:

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with hypertension receiving bevacizumab for breast cancer. Studying samples of germline DNA in the laboratory from patients with hypertension receiving bevacizumab for breast cancer may help doctors learn about changes that occur in DNA and identify biomarkers related to hypertension.


Study summary:

PRIMARY OBJECTIVES: I. To identify, using next generation sequencing, rare variants of large effect size that impact the risk of hypertension in patients from the clinical trial Eastern Cooperative Oncology Group (ECOG)-5103 (E5103). OUTLINE: Previously collected germline DNA samples are analyzed via whole exome sequencing.


Criteria:

Inclusion Criteria: - European American patients with deoxyribonucleic acid (DNA) available and designated case or control - Patients who developed grade 3-4 bevacizumab-induced hypertension during their treatment with bevacizumab - Patients who did not develop hypertension following a full course of treatment with bevacizumab


NCT ID:

NCT02610413


Primary Contact:

Principal Investigator
Bryan P Schneider
Eastern Cooperative Oncology Group


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02215
United States

Bryan P. Schneider
Phone: 317-274-6473
Email: bpschnei@iupui.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.